相关实验视频
Updated: Mar 11, 2026

10:42
A Free-breathing fMRI Method to Study Human Olfactory Function
Published on: July 30, 2017
10.2K
在主观认知衰退,轻度认知障碍和阿尔茨海默氏症痴呆症中单一的气味识别
Abdallah Tasnim1, Johann Lehrner2
1Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Wiener klinische Wochenschrift
|March 9, 2026
概括
嗅觉功能障碍,特别是识别特定气味的缺陷,可能表明早期阿尔茨海默氏症痴呆症 (AD) 和认知能力下降. 嗅探棒的测试显示了早期AD检测的希望.
科学领域:
- 神经科学是一个神经科学.
- 老年学是指老年学的学科.
- 临床神经学 临床神经学
背景情况:
- 嗅觉功能障碍是阿尔茨海默氏症痴呆症 (AD) 和认知障碍的早期生物标志物.
- 这项研究调查了各种认知障碍阶段的特定气味嗅觉缺陷.
研究的目的:
- 评估特定气味在区分主观认知衰退 (SCD),轻度认知障碍 (MCI) 和AD与健康对照 (HC) 中的区分有效性.
- 分析年龄,性别,口语智力和抑郁症对嗅觉表现的影响.
- 在物流回归分析中,将参与者分为AD类别和非AD类别.
主要方法:
- 维也纳医学大学对50岁以上的737名参与者的回顾性分析.
- 嗅觉识别通过使用16项Sniffin' Sticks气味识别测试进行评估.
- 评估了特定气味的区分能力,以区分AD与非AD组,并应用Bonferroni校正.
主要成果:
- 在诊断组中观察到明显的气味识别差异,阿兹海默症患者表现出最明显的缺陷 (针,,).
- 年龄与嗅觉表现负相关;较高的口语智力具有保护性.
- 关键的气味将AD与非AD组区分开来,表明了诊断潜力.
结论:
- 特定于气味的缺陷是认知能力下降的早期指标.
- 嗅探棒测试和关键气味可能有助于早期检测和区分认知障碍.
- 计算共变量可以提高诊断的准确性;为了更广泛的临床实用性,需要进一步的研究.
相关概念视频
Olfaction
49.4K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
49.4K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Olfactory Receptors: Location and Structure
13.6K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
13.6K
Dementia
636
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
636
Physiology of Smell and Olfactory Pathway
13.6K
Humans detect odors with the help of specialized cells located in the upper part of the nasal cavity, called olfactory receptor neurons (ORNs). ORNs possess hair-like structures called cilia, which are receptive to sensations from the inhaled air. When an odorant molecule binds to a specific receptor on the cell of the cilia, it leads to a series of events that ultimately cause the ORN to send electrical signals to the olfactory bulb in the brain through the olfactory nerves.
The olfactory...
The olfactory...
13.6K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

